The use of two measures of health-related quality of life in HIV-infected individuals: A cross-sectional comparison

Quality of Life Research

Volumn 5, Issue 2, 1996, Pages 281-286

  Copfer, A E ^a   Ampel, N M ^a,b   Hughes, T E ^c   Gregor, K J ^c   Dols, C L ^a   Coons, S J ^c   Colgan, K ^a   Wu, A W ^d  

^a SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c College of Pharmacy ^*

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Acquired immunodeficiency Syndrome; Health status; HIV infection; Quality of life; Questionnaires

Indexed keywords

DIDANOSINE; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE;

ADULT; ARIZONA; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LINEAR MODELS; MALE; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; STATISTICS, NONPARAMETRIC;

EID: 0029981055     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00434750     Document Type: Article

References (26)

1. Pantaleo G, Graziosi C, Fauci AS. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993; 328: 327-335.
2. Hamilton JD, Hartigan PM, Simberkoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. N Engl J Med 1992; 326: 437-443.
3. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871-881.
4. Melbye M, Biggar RJ, Ebbesen P, et al. Long-term seropositivity for human T-lymphocyte virus type III in homosexual men without the acquired immunodeficiency syndrome: development of immunologic and clinical abnormalities. Ann Intern Med 1986; 104: 496-500.
5. Fahey JL, Taylor JMG, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990; 322: 166-172.
6. de Boer JB, van Dam FSAM, Sprangers MAG, Frissen PHJ, Lange JMA. Longitudinal study on the quality of life of symptomatic HIV-infected patients in a trial of zidovudine versus zidovudine and interferon-α. AIDS 1993; 7: 947-953.
7. Gelber RD, Lenderking WR, Cotton DJ, et al. Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. Ann Intern Med 1992; 116: 961-966.
8. Kaplan RM, Anderson JP, Wu AW, Mathews WC, Kozin F, Orenstein D. The Quality of Well-Being Scale: Applications in AIDS, cystic fibrosis, and arthritis. Med Care 1989; 27: S27-S43.
9. Lenderking WR, Gelber RD, Cotton DJ, et al. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. N Engl J Med 1994; 330: 738-743.
10. Lubeck DP, Bennett CL, Mazonson PD, Fifer S, Fries JF. Quality of life and health service use among HIV-infected patients with chronic diarrhea. J Acquir Immune Defic Syndr 1993; 6: 478-484.
11. Wachtel T, Piette J, Mor V, Stein M, Fleishman J, Carpenter C. Quality of life in persons with human immunodeficiency virus: measurement by the medical outcomes study instrument. Ann Int Med 1992; 116: 129-137.
12. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study: Preliminary validation in persons with early HIV infection. Med Care 1991; 29: 786-798.
13. Bozzette SA, Kanouse DE, Berry S, Duan N. Health status and function with zidovudine or zalcitabine as initial therapy for AIDS. A randomized controlled trial. JAMA 1995; 273: 295-301.
14. Burgess A, Dayer M, Catalan J, Hawkins D, Gazzard B. The reliability and validity of two HIV-specific health-related quality-of-life measures: a preliminary analysis. AIDS 1993; 7: 1001-1008.
15. Schag CA, Ganz PA, Kahn B, Petersen L. Assessing the needs and quality of life of patients with HIV infection: development of the HIV Overview of Problems - Evaluation System (HOPES). Qual Life Res 1992; 1: 397-113.
16. Kaplan RM, Bush JW, Berry CC. Health status: types of validity and the index of well-being. Health Services Res 1976.
17. Kaplan RM, Atkins CJ, Timms R. Validity of a quality of well-being scale as an outcome measure in chronic obstructive pulmonary disease. J Chron Dis 1984; 2: 85-95.
18. Wu AW, Mathews WC, Brysk LT, et al. Quality of life in a placebo-controlled trial of zidovudine in patients with AIDS and AIDS-related complex. J Acquir Immune Defic Syndr 1990; 3: 683-690.
19. Stewart AL, Hays RD, Ware JE Jr. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 1988; 26: 724-735.
20. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, ed. Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press, 1949: 199-205.
21. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41(No RR-17): 1-19.
22. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16: 297-335.
23. Soakl RR, Rohlf FJ. Biometry. The principles and practice of statistics in biological research. San Francisco: WH Freeman and Company, 1981: 1-859.
24. McHorney CA, Ware JE Jr, Rogers W, Raczek AE, Lu JFR. The validity and relative precision of MOS short-and long-form status scales and Dartmouth COOP charts. Med Care 1992; 30: MS253-MS265.
25. Fryback DG, Dasbach ED, Klein R, et al. Health assessment by SF-36, Quality of Well-Being Index, and Time-Trade-offs: predicting one measure from another [abstract]. Med Decis Making 1992; 12: 348.
26. Wu AW, Lamping DL. Assessment of quality of life in HIV disease. AIDS 1994; 8(Suppl): S349-S359.